Answers are grounded in this paper and cite their sources.
Evaluates 1F10 antibody's potential to clear amyloid fibrils in AL amyloidosis, suggesting an effective treatment option.
Light chain (AL) amyloidosis is a fatal plasma cell dyscrasia characterized by the overproduction of misfolded l or k immunoglobulin light chains (LCs) produced by clonal plasma cells, which aggregate into amyloid fibrils that deposit in tissues and cause progressive organ damage. While current anti-plasma cell therapies reduce the production of new amyloidogenic LCs, pre-existing fibrils persist and continue to drive organ damage. Amyloid-targeting monoclonal antibodies birtamimab and anselamimab were developed and tested for active AL amyloid clearance; however, they failed to meet the primary endpoint in Phase 3 trials, presumably due to insufficient binding affinity for l LC amyloid, which occurs in ~80% of patients. Here, we reported the development of 1F10, a novel high-affinity l subtype-specific amyloid-binding monoclonal antibody that does not cross-react with soluble native l or k LCs. 1F10 exhibits superior binding affinity to l AL amyloid fibrils and significantly enhances antibody-dependent phagocytosis (ADP) of l AL amyloid compared with birtamimab and anselamimab. Specific binding of 1F10 to l amyloid is confirmed by immunohistochemical staining of patient-derived tissue biopsies. Importantly, 1F10 demonstrates robust in vivo activity, significantly accelerating the resolution of l amyloid fibrils in an AL amyloidoma mouse model. Together, these findings establish 1F10 antibody as a promising subtype-specific immunotherapeutic candidate for targeting l LC amyloid, addressing a critical unmet need for the majority of patients with AL amyloidosis.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: